全身性真菌感染症のリスクが高い2歳以上15歳未満の小児におけるボリコナゾールの薬物動態および安全性に関する研究

基本情報

NCT ID

NCT01383993

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

21

治験依頼者名

Pfizer

概要

In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down. Since we know the dose in adults, and we think we know the matching doses in the young patients ages 2 to less than 15 years old, we will compare the amount of drug that goes into the system with what we know works in adults. We give the drug by a needle directly into the blood, then few days later we stop that and give the drug by mouth. Meanwhile, we draw a little bit of blood at certain times to measure the drug in it.

対象疾患

介入

依頼者（Sponsor）

実施施設 (6)